Finerenone is a selective, nonsteroidal MR antagonist with demonstrated CV and kidney benefits in patients with CKD and T2D in two complementary phase 3 trials, where the combined patient populations covered the spectrum of CKD severity: FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease (FIDELIO-DKD, NCT02540993) and FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease (FIGARO-DKD, NCT02545049) (20). The gene discussed is NR3C2; the disease is diabetic kidney disease.